News and Trends 26 Jul 2017 German Biotech Publishes First-in-Human Data on Rabies mRNA Vaccine CureVac has published proof-of-concept data for an mRNA rabies vaccine that could open the door for a new generation of better and cheaper vaccines. CureVac, based in Tübingen, Germany, is a pioneer in the development of therapeutic mRNA technology. The company has published today in The Lancet proof-of-concept data from a Phase I trial testing CV7201, […] July 26, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2017 Dutch Biotech Reports Positive Phase II Data on Rare Inflammatory Disease Pharming has published Phase II data in The Lancet supporting its lead candidate as a treatment for the rare genetic disease hereditary angioedema. Pharming, one of the top biotechs in Leiden, specializes in recombinant protein technology. Its lead compound, ruconest, is a recombinant human C1 inhibitor protein. The results of a 32-patient Phase II study published […] July 26, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2017 Update: Potential Breakthrough Treatment for Deadly Lung Disease Starts Phase IIb Update (26/07/2017): Verona Pharma has dosed the first patients in the PhaseIIb with RPL554 in patients with chronic obstructive pulmonary disease (COPD). Results are expected in the second half of 2018. Published on 27/06/2017 Verona Pharma has secured regulatory approval in five European countries to run a Phase IIb trial with its dual PDE3/4 inhibitor in […] July 26, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jul 2017 How can Recombinant Proteins be used in Veterinary Medicine? This expert has told us why recombinant proteins are an elegant way to go in the production of veterinary vaccines and why glycosylation patterns can play a big part in all of it! For many decades, human blood plasma has been a source of different biotherapeutic proteins, including antibodies, albumin and blood coagulation factors. Although they are […] July 24, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2017 Roche Abandons Spanish Cancer Epigenetics Drug Roche has decided to terminate its license agreement with Spanish biotech Oryzon Genomics after rearranging its portfolio priorities. Oryzon Genomics, a biotech based in Barcelona working on epigenetics, was notified yesterday by Roche about the discontinuation of their deal concerning the biotech’s lead candidate, ORY-1001. Roche announced the decision was not based on clinical data, […] July 21, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2017 Update: Danish Psoriasis Drug Gets EU Approval Despite Suicide Links Update (20/07/2017): The European Commision has granted LEO Pharma marketing authorization for Kyntheum (brodalumab), making it the first biologic drug that targets IL-17a. Published 22/05/2017 The EMA has taken up a positive opinion for Leo Pharma’s psoriasis drug brodalumab, even though the drug has been associated with suicidal behavior. Brodalumab, a fully human antibody targeting the […] July 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2017 Sanofi Offers up to €2.4Bn to Belgian Biotech to Develop Nanobodies Ablynx and Sanofi have entered a research collaboration and exclusive licensing agreement for up to eight nanobody candidates for immune and inflammatory disease. Ablynx, based in Belgium, develops nanobodies, single-domain antibodies inspired on those of camels and llamas that have the advantage of being much smaller than standard antibodies. This technology has caught the attention of Sanofi, […] July 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2017 FREE White Paper! All You need to Know about Omics and Body Fat What do you think when you hear the word ‘lipid’? I bet your thoughts include fat, energy, hormones, maybe cells? But what if I told you that lipids can also be considered as biomarkers? Very important biomarkers too that can be analyzed and identified using multiparametric statistical analysis! With more and more research focusing on […] July 19, 2017 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2017 Update: British Biotech Starts Phase II Trial in the Second Deadliest Cancer Update (19/07/2017): Tiziana has enrolled its first patient with refractory hepatocellular carcinoma in the Phase IIa trial with milciblib. Results are expected in the fourth quarter of 2018. Published on 24/04/2017 Tiziana Life Sciences has received approval to start Phase II in Israel with its leading compound, a CDK inhibitor targeting one of the deadliest cancers. […] July 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2017 Shire In-Licenses Swiss Antibody for Hemophilia A to Compete with Roche Shire has bought exclusive worldwide rights to develop and commercialize a bispecific antibody from Novimmune that could improve the treatment of hemophilia A. Novimmune is a biotech from Geneva that specializes in developing antibodies. Back in 2015, it struck a research collaboration with Baxalta, which has since been acquired Shire. The Irish pharma has now decided to […] July 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2017 German Biotech Strikes License Deal with Japanese Dermatology Firm 4SC has granted an exclusive worldwide license to the Japanese dermatology firm Maruho on a class of compounds against the Kv1.3 ion channel. Under the agreement, 4SC could receive up to €105M in upfront and milestone payments plus royalties on future sales. The deal is part of the German company’s strategy to out license non-core […] July 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jul 2017 A Brand New Outlook on Induced Pluripotent Stem Cells In an exclusive interview with Dr David Hallett, we discover why iPS cells are the perfect replacement for human embryonic stem cells, what is so unique about them and the challenges researchers face in the field! Talk of using human stem cells to better understand and even cure diseases has been around for a few decades. […] July 17, 2017 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email